

Nikhil C Munshi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5910527/nikhil-c-munshi-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

450
papers

30,966
citations

80
h-index

173
g-index

477
ext. papers

37,522
ext. citations

5.6
avg, IF

6.52
L-index

#	Paper	IF	Citations
450	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013 , 500, 415-21	50.4	5895
449	Antitumor activity of thalidomide in refractory multiple myeloma. <i>New England Journal of Medicine</i> , 1999 , 341, 1565-71	59.2	2139
448	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. <i>Lancet Oncology, The</i> , 2016 , 17, e328-e346	21.7	1155
447	NF-kappa B as a therapeutic target in multiple myeloma. <i>Journal of Biological Chemistry</i> , 2002 , 277, 16639-47	9.47	723
446	Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2010 , 116, 679-86	2.2	680
445	Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019 , 380, 1726-1737	59.2	672
444	Molecular sequelae of proteasome inhibition in human multiple myeloma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 14374-9	11.5	630
443	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017 , 376, 1311-1320	59.2	608
442	Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. <i>Blood</i> , 2002 , 99, 4525-30	2.2	576
441	Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. <i>Nature Communications</i> , 2014 , 5, 2997	17.4	564
440	Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 540-5	11.5	496
439	Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. <i>Blood</i> , 2001 , 98, 492-4	2.2	474
438	Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. <i>Oncogene</i> , 2002 , 21, 5673-83	9.2	423
437	Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. <i>Blood</i> , 2008 , 112, 1329-37	2.2	366
436	Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. <i>Blood</i> , 2009 , 114, 371-2	2.2	331
435	The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. <i>Cancer Cell</i> , 2007 , 11, 349-60	24.3	315
434	Blockade of XBP1 splicing by inhibition of IRE1 β s a promising therapeutic option in multiple myeloma. <i>Blood</i> , 2012 , 119, 5772-81	2.2	296

433	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2021 , 384, 705-716	59.2	287
432	Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> , 2014 , 123, 3128-38	2.2	273
431	Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. <i>JAMA Oncology</i> , 2017 , 3, 28-35	13.4	273
430	Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. <i>Blood</i> , 2013 , 121, 2975-87	2.2	268
429	Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. <i>Blood</i> , 2000 , 95, 4008-4010	2.2	262
428	Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. <i>Blood</i> , 2011 , 117, 4696-700	2.2	252
427	Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. <i>Blood</i> , 2010 , 115, 5385-92	2.2	247
426	Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. <i>Blood</i> , 2004 , 103, 1787-90	2.2	230
425	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. <i>ELife</i> , 2014 , 3,	8.9	229
424	Prognostic significance of copy-number alterations in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4585-90	2.2	216
423	Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4607-18	12.9	214
422	Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3518-25	2.2	213
421	Results of autologous stem cell transplant in multiple myeloma patients with renal failure. <i>British Journal of Haematology</i> , 2001 , 114, 822-9	4.5	212
420	Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. <i>Cancer Cell</i> , 2009 , 16, 309-23	24.3	197
419	Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. <i>Blood</i> , 2018 , 132, 587-597	2.2	196
418	Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. <i>Blood</i> , 2003 , 102, 4504-11	2.2	194
417	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018 , 132, 2456-2464	2.2	191
416	Dysfunctional T regulatory cells in multiple myeloma. <i>Blood</i> , 2006 , 107, 301-4	2.2	188

415	Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. <i>Cancer Research</i> , 2006 , 66, 6675-82	10.1	187
414	Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. <i>Clinical Cancer Research</i> , 2012 , 18, 6260-70	12.9	185
413	Pathogenesis beyond the cancer clone(s) in multiple myeloma. <i>Blood</i> , 2015 , 125, 3049-58	2.2	181
412	The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. <i>Clinical Cancer Research</i> , 2009 , 15, 4028-37	12.9	178
411	A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. <i>Leukemia</i> , 2019 , 33, 159-170	10.7	176
410	Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. <i>Blood</i> , 2008 , 111, 1654-64	2.2	174
409	Prospective Evaluation of Magnetic Resonance Imaging and [F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2911-2918	2.2	172
408	Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. <i>Blood</i> , 2010 , 116, 3227-37	2.2	172
407	Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. <i>Blood</i> , 2011 , 117, 393-402	2.2	169
406	APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. <i>Blood</i> , 2016 , 127, 3225-36	2.2	168
405	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , 2004 , 104, 4188-93	2.2	167
404	Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. <i>British Journal of Haematology</i> , 2001 , 114, 600-7	4.5	165
403	Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. <i>Oncogene</i> , 2002 , 21, 1346-58	9.2	157
402	Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. <i>Blood</i> , 2005 , 106, 1042-7	2.2	152
401	Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. <i>Blood</i> , 2012 , 120, 1877-87	2.2	150
400	Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. <i>Cancer Research</i> , 2005 , 65, 11712-20	10.1	149
399	Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. <i>British Journal of Haematology</i> , 2006 , 135, 158-64	4.5	144
398	Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5713-9	2.2	141

397	Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 4290-4300	12.9	139
396	In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. <i>Cancer Research</i> , 2004 , 64, 4629-36	10.1	139
395	Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. <i>Blood</i> , 2011 , 118, 675-8	2.2	136
394	Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. <i>Blood</i> , 2006 , 108, 2804-10	2.2	135
393	Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. <i>Leukemia</i> , 2018 , 32, 1948-1957	10.7	129
392	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i> , 2018 , 132, 2115-2124	2.2	127
391	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015 , 21, 4055-61	12.9	126
390	Identification of genes modulated in multiple myeloma using genetically identical twin samples. <i>Blood</i> , 2004 , 103, 1799-806	2.2	120
389	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet, The</i> , 2021 , 398, 314-324	40	118
388	Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. <i>Clinical Cancer Research</i> , 2007 , 13, 5903-9	12.9	116
387	A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. <i>Haematologica</i> , 2010 , 95, 845-8	6.6	115
386	Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. <i>Blood</i> , 2004 , 104, 3688-96	2.2	111
385	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014 , 124, 1404-11	2.2	107
384	New strategies in the treatment of multiple myeloma. <i>Clinical Cancer Research</i> , 2013 , 19, 3337-44	12.9	104
383	Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. <i>Clinical Cancer Research</i> , 2004 , 10, 770-6	12.9	104
382	Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. <i>Blood</i> , 2012 , 120, 3519-29	2.2	100
381	Genomic patterns of progression in smoldering multiple myeloma. <i>Nature Communications</i> , 2018 , 9, 33637.4	7.4	99
380	Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. <i>Blood</i> , 2016 , 128, 1590-603	2.2	99

379	Genomic landscape and chronological reconstruction of driver events in multiple myeloma. <i>Nature Communications</i> , 2019 , 10, 3835	17.4	94
378	Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. <i>British Journal of Haematology</i> , 2007 , 138, 783-91	4.5	94
377	Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. <i>Blood</i> , 2009 , 113, 2290-7	2.2	90
376	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. <i>Leukemia</i> , 2018 , 32, 2604-2616	10.7	90
375	Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. <i>Clinical Cancer Research</i> , 2005 , 11, 4251-8	12.9	88
374	Use of a claims database to characterize and estimate the incidence rate for Castleman disease. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1252-60	1.9	84
373	Anti-myeloma activity of pamidronate in vivo. <i>British Journal of Haematology</i> , 1998 , 103, 530-2	4.5	83
372	Genetics of multiple myeloma: another heterogeneity level?. <i>Blood</i> , 2015 , 125, 1870-6	2.2	81
371	Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). <i>Blood</i> , 2015 , 126, 391-391	2.2	80
370	A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2016 , 22, 1222-33	12.9	79
369	Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. <i>Journal of Cellular Biochemistry</i> , 2007 , 101, 950-68	4.7	77
368	Optimizing dendritic cell-based immunotherapy in multiple myeloma. <i>British Journal of Haematology</i> , 2002 , 117, 297-305	4.5	77
367	Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1364-75	6.1	75
366	A practical guide for mutational signature analysis in hematological malignancies. <i>Nature Communications</i> , 2019 , 10, 2969	17.4	73
365	Genomics in multiple myeloma. <i>Clinical Cancer Research</i> , 2011 , 17, 1234-42	12.9	73
364	ILF2 Is a Regulator of RNA Splicing and DNA Damage Response in 1q21-Amplified Multiple Myeloma. <i>Cancer Cell</i> , 2017 , 32, 88-100.e6	24.3	72
363	Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1225-34	6.3	72
362	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. <i>British Journal of Haematology</i> , 2018 , 182, 222-230	4.5	70

361	Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. <i>Cancer Research</i> , 2015 , 75, 4384-4397	10.1	69
360	Multicolour spectral karyotyping identifies new translocations and a recurring pathway for chromosome loss in multiple myeloma. <i>British Journal of Haematology</i> , 2001 , 112, 167-74	4.5	69
359	Genomics of Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 963-967	2.2	68
358	Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8503-8503	2.2	68
357	Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. <i>Blood</i> , 2016 , 127, 1138-50	2.2	68
356	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. <i>Cell Reports</i> , 2017 , 19, 218-224	6.6	67
355	Widespread intronic polyadenylation diversifies immune cell transcriptomes. <i>Nature Communications</i> , 2018 , 9, 1716	17.4	66
354	Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. <i>Blood</i> , 2015 , 125, 2095-100	2.2	64
353	A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 5988-5999	7.8	62
352	Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. <i>Blood</i> , 2009 , 113, 5228-36	2.2	62
351	The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. <i>Nature Communications</i> , 2016 , 7, 10258	17.4	61
350	The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. <i>Nature Medicine</i> , 2015 , 21, 572-80	50.5	60
349	Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. <i>Clinical Cancer Research</i> , 2015 , 21, 4294-304	12.9	59
348	Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy. <i>Blood</i> , 2017 , 130, 740-740	2.2	58
347	Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. <i>Clinical Cancer Research</i> , 2012 , 18, 4850-60	12.9	57
346	Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. <i>Nature Communications</i> , 2021 , 12, 868	17.4	54
345	Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. <i>Clinical Cancer Research</i> , 2008 , 14, 6955-62	12.9	52
344	Growth arrest, apoptosis, and telomere shortening of Barrett's-associated adenocarcinoma cells by a telomerase inhibitor. <i>Gastroenterology</i> , 2004 , 126, 1337-46	13.3	52

343	The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. <i>Clinical Cancer Research</i> , 2017 , 23, 3980-3993	12.9	51
342	Multiple myeloma clonal evolution in homogeneously treated patients. <i>Leukemia</i> , 2018 , 32, 2636-2647	10.7	51
341	Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 372-380	2	48
340	Pyk2 promotes tumor progression in multiple myeloma. <i>Blood</i> , 2014 , 124, 2675-86	2.2	48
339	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2380-2389	2.2	46
338	A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. <i>Clinical Cancer Research</i> , 2004 , 10, 5692-701	12.9	45
337	Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 4280-4289	12.9	44
336	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. <i>British Journal of Haematology</i> , 2015 , 169, 851-8	4.5	44
335	CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020 , 136, 22-25	2.2	44
334	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. <i>British Journal of Haematology</i> , 2015 , 169, 843-50	4.5	42
333	Differential and limited expression of mutant alleles in multiple myeloma. <i>Blood</i> , 2014 , 124, 3110-7	2.2	42
332	A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. <i>Blood</i> , 2016 , 128, 249-52	2.2	41
331	Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92. <i>Blood</i> , 2018 , 132, 1050-1063	2.2	40
330	APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. <i>Leukemia</i> , 2019 , 33, 426-438	10.7	40
329	Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes. <i>Blood</i> , 2020 , 136, 25-26	2.2	39
328	CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis. <i>PLoS ONE</i> , 2014 , 9, e97566	3.7	38
327	Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 691-698	9.7	37
326	Timing the initiation of multiple myeloma. <i>Nature Communications</i> , 2020 , 11, 1917	17.4	36

325	Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages. <i>Onc Immunology</i> , 2016 , 5, e1189052	7.2	36
324	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. <i>Blood Advances</i> , 2018 , 2, 2937-2946	7.8	36
323	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020 , 11, 2996	17.4	34
322	Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. <i>Clinical Cancer Research</i> , 2008 , 14, 4971-80	12.9	34
321	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021 , 22, e119-e130	21.7	33
320	A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. <i>Oncotarget</i> , 2016 , 7, 77326-77341	3.3	33
319	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology, The</i> , 2021 , 22, e105-e118	21.7	32
318	A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2016 , 22, 4350-4355	12.9	32
317	Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. <i>Leukemia</i> , 2018 , 32, 2626-2635	10.7	31
316	Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. <i>Cancer Research</i> , 2016 , 76, 463-71	10.1	31
315	A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. <i>British Journal of Haematology</i> , 2012 , 157, 687-701	4.5	31
314	A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. <i>Leukemia</i> , 2020 , 34, 2150-2162	10.7	29
313	Review of siltuximab in the treatment of multicentric Castleman's disease. <i>Therapeutic Advances in Hematology</i> , 2016 , 7, 360-366	5.7	29
312	Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. <i>Blood</i> , 2019 , 134, 160-170	2.2	28
311	Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation. <i>Nature Communications</i> , 2017 , 8, 1613	17.4	28
310	Revealing the impact of structural variants in multiple myeloma. <i>Blood Cancer Discovery</i> , 2020 , 1, 258-273		28
309	Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. <i>Leukemia</i> , 2020 , 34, 1866-1874	10.7	27
308	Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. <i>Clinical Cancer Research</i> , 2014 , 20, 3955-61	12.9	27

307	Case records of the Massachusetts General Hospital. Case 13-2008. A 46-year-old man with rheumatoid arthritis and lymphadenopathy. <i>New England Journal of Medicine</i> , 2008 , 358, 1838-48	59.2	27
306	p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2017 , 129, 1308-1319	2.2	26
305	Genomic heterogeneity in multiple myeloma. <i>Current Opinion in Genetics and Development</i> , 2015 , 30, 56-65	4.9	26
304	Deep Response in Multiple Myeloma: A Critical Review. <i>BioMed Research International</i> , 2015 , 2015, 832049	3.9	26
303	Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial. <i>Blood</i> , 2020 , 136, 39-39	2.2	26
302	Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. <i>Blood</i> , 2017 , 129, 2233-2245	2.2	25
301	Deciphering the chronology of copy number alterations in Multiple Myeloma. <i>Blood Cancer Journal</i> , 2019 , 9, 39	7	25
300	Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. <i>British Journal of Haematology</i> , 2011 , 155, 349-61	4.5	25
299	Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review. <i>JAMA Oncology</i> , 2020 , 6, 425-432	13.4	25
298	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019 , 94, 1244-1253	7.1	24
297	International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. <i>Blood Advances</i> , 2020 , 4, 6039-6050	7.8	24
296	Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. <i>Leukemia</i> , 2018 , 32, 1838-1841	10.7	24
295	DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. <i>Blood</i> , 2016 , 128, 1214-25	2.2	24
294	Safety Data from a First-in-Human Phase 1 Trial of NKG2D Chimeric Antigen Receptor-T Cells in AML/MDS and Multiple Myeloma. <i>Blood</i> , 2016 , 128, 4052-4052	2.2	23
293	Diagnosis of Castleman Disease. <i>Hematology/Oncology Clinics of North America</i> , 2018 , 32, 53-64	3.1	23
292	Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance. <i>Blood Cancer Journal</i> , 2018 , 8, 92	7	23
291	Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. <i>Leukemia</i> , 2021 , 35, 752-763	10.7	22
290	Early Evidence of Anabolic Bone Activity of BHQ880, a Fully Human Anti-DKK1 Neutralizing Antibody: Results of a Phase 2 Study in Previously Untreated Patients with Smoldering Multiple Myeloma At Risk for Progression. <i>Blood</i> , 2012 , 120, 331-331	2.2	21

289	Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8 cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. <i>Leukemia</i> , 2019 , 33, 2208-2226	10.7	20
288	Mechanism of action of immunomodulatory agents in multiple myeloma. <i>Medical Oncology</i> , 2010 , 27 Suppl 1, S7-13	3.7	20
287	The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. <i>Blood Advances</i> , 2020 , 4, 4195-4207	7.8	20
286	Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2017 , 23, 5225-5237	12.9	19
285	Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3107-3118	2.2	19
284	Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. <i>Cancer Research</i> , 2020 , 80, 2031-2044	10.1	19
283	Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. <i>Oncotarget</i> , 2014 , 3, e970914	7.2	18
282	Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. <i>Clinical Cancer Research</i> , 2016 , 22, 6099-6109	12.9	17
281	Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016 , 34, e1-5	2.2	16
280	Logic programming reveals alteration of key transcription factors in multiple myeloma. <i>Scientific Reports</i> , 2017 , 7, 9257	4.9	16
279	Combination of a Selective HSP90 α Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2015 , 10, e0143847	3.7	16
278	AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo. <i>Blood</i> , 2019 , 134, 135-135	2.2	16
277	BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8 cytotoxic T lymphocytes against multiple myeloma: clinical applications. <i>Leukemia</i> , 2020 , 34, 210-223	10.7	16
276	The shaping and functional consequences of the dosage effect landscape in multiple myeloma. <i>BMC Genomics</i> , 2013 , 14, 672	4.5	15
275	Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. <i>Blood Cancer Discovery</i> , 2021 , 2, 468-483	7	15
274	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. <i>Cancers</i> , 2020 , 12,	6.6	14
273	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 804-804	2.2	14
272	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, 332-344	2	13

271	Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOBs as a novel target for multiple myeloma. <i>British Journal of Haematology</i> , 2013 , 163, 343-51	4.5	13
270	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2016 , 128, 976-976	2.2	13
269	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma 2020 , 8,		13
268	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1609-1618	4	13
267	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 641-648	4.7	13
266	Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019 , 25, 369-377	12.9	13
265	VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. <i>Blood Cancer Journal</i> , 2020 , 10, 110	7	12
264	Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients. <i>Clinical Cancer Research</i> , 2016 , 22, 4039-44	12.9	11
263	Immunotherapy strategies in multiple myeloma. <i>Hematology/Oncology Clinics of North America</i> , 2014 , 28, 927-43	3.1	11
262	Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma. <i>Leukemia</i> , 2020 , 34, 578-588	10.7	11
261	Risk factors in multiple myeloma: is it time for a revision?. <i>Blood</i> , 2021 , 137, 16-19	2.2	11
260	Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. <i>Cell Reports</i> , 2018 , 25, 3693-3705.e6	10.6	11
259	Deficiency of IL-17A, but not the prototypical Th17 transcription factor ROR γ , decreases murine spontaneous intestinal tumorigenesis. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 13-24	7.4	10
258	Investigative tools for diagnosis and management. <i>Hematology American Society of Hematology Education Program</i> , 2008 , 298-305	3.1	10
257	Secondary Quality-of-Life Domains in Patients with Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel; bb2121): Results from the Karmma Clinical Trial. <i>Blood</i> , 2020 , 136, 28-29	2.2	10
256	Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. <i>Blood</i> , 2008 , 112, 3696-3696	2.2	10
255	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 23-23	2.2	10
254	Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. <i>Cancer Research</i> , 2021 , 81, 713-723	10.1	10

253	Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). <i>Blood</i> , 2018 , 132, 2778-2780	2.2	10
252	A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2015 , 169, 36-43	4.5	9
251	Immunotherapy for multiple myeloma. <i>Expert Review of Hematology</i> , 2014 , 7, 91-6	2.8	9
250	Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles. <i>PLoS ONE</i> , 2013 , 8, e58809	3.7	9
249	Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 548-548	2.2	9
248	Updated Results from CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 549-549	2.2	9
247	Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. <i>JAMA Oncology</i> , 2021 ,	13.4	9
246	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. <i>Blood Advances</i> , 2019 , 3, 3360-3374	7.8	9
245	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e7-e15	4.7	9
244	Next-generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. <i>Cancer</i> , 2017 , 123, 3701-3708	6.4	8
243	Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 422-430	2	8
242	Novel biologically based therapies for multiple myeloma. <i>International Journal of Hematology</i> , 2002 , 76 Suppl 1, 340-1	2.3	8
241	Amplification and overexpression of E2 ubiquitin conjugase UBE2T promotes homologous recombination in multiple myeloma. <i>Blood Advances</i> , 2019 , 3, 3968-3972	7.8	8
240	Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 14-14	2.2	7
239	A Phase I, Multi-Center, Dose Escalation Study of Atiprimod in Patients with Refractory or Relapsed Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 111-111	2.2	7
238	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy and Safety Of Siltuximab, An Anti-Interleukin-6 Monoclonal Antibody, In Patients With Multicentric Castleman Disease. <i>Blood</i> , 2013 , 122, 505-505	2.2	7
237	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3454-3454	2.2	7
236	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4217-4217	2.2	7

235	Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.. <i>Lancet Haematology,the</i> , 2022 , 9, e143-e161	14.6	6
234	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018 , 132, 749-749	2.2	6
233	High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 4-5	2.2	6
232	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. <i>Blood</i> , 2008 , 112, 832-832	2.2	6
231	BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. <i>Clinical Cancer Research</i> , 2021 ,	12.9	6
230	Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. <i>Leukemia</i> , 2021 ,	10.7	6
229	Next-Generation Sequencing Informing Therapeutic Decisions and Personalized Approaches. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e442-8	7.1	6
228	Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3CD8 T cells against Various Solid Tumors. <i>Journal of Leukemia (Los Angeles, Calif)</i> , 2015 , 3,		5
227	Immune therapies. <i>Hematology/Oncology Clinics of North America</i> , 2007 , 21, 1217-30, x-xi	3.1	5
226	Recent advances in the management of multiple myeloma. <i>Seminars in Hematology</i> , 2004 , 41, 21-6	4	5
225	Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett's Adenocarcinoma Cells. <i>Journal of Gastroenterology and Hepatology Research</i> , 2017 , 6, 2286-2295	0.9	5
224	Detection of minimal residual disease by next generation sequencing in AL amyloidosis. <i>Blood Cancer Journal</i> , 2021 , 11, 117	7	5
223	The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. <i>Leukemia</i> , 2020 , 34, 167-179	10.7	5
222	Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, MAIA. <i>Blood</i> , 2021 ,	2.2	5
221	Deficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis. <i>OncImmunology</i> , 2017 , 6, e1261776	7.2	4
220	c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma. <i>European Journal of Haematology</i> , 2020 , 105, 35-46	3.8	4
219	With Equal Access, African Americans with Non-del17p Multiple Myeloma Have Superior Overall Survival, but del17p Still Carries Poor Prognosis across Race: A VA Study. <i>Blood</i> , 2019 , 134, 4388-4388	2.2	4
218	Comprehensive Genome-Wide Profile of Regional Gains and Losses in Multiple Myeloma Using Array-CGH: The 1q21 Amplification and Potential Role of the BCL-9 Gene in Multiple Myeloma Pathogenesis.. <i>Blood</i> , 2004 , 104, 785-785	2.2	4

217	Phase I Trial of HuLuc63 in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 1180-1180	2.2	4
216	AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β <i>Blood</i> , 2008 , 112, 251-251	2.2	4
215	miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. <i>Blood</i> , 2021 , 137, 1905-1919	2.2	4
214	Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2021 , 2, 370-387	7	4
213	Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. <i>American Journal of Hematology</i> , 2021 , 96, 896-900	7.1	4
212	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. <i>Clinical Cancer Research</i> , 2021 ,	12.9	4
211	Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. <i>Lancet Haematology</i> , 2021 , 8, e794-e807 ^{14.6}		4
210	YWHAE/14-3-3β expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. <i>Blood</i> , 2020 , 136, 468-479	2.2	3
209	Plasma Cell Neoplasms 2018 , 1381-1418.e1		3
208	To transplant or not to transplant?. <i>Blood</i> , 2005 , 106, 3687-3688	2.2	3
207	Don't Compromise Myeloma Care Due to COVID-19 Pandemic!. <i>Blood Cancer Discovery</i> , 2020 , 1, 218-220	7	3
206	MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells. <i>Blood</i> , 2019 , 134, 3096-3096	2.2	3
205	IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.. <i>Blood</i> , 2004 , 104, 2403-2403	2.2	3
204	Anti-Tumor Activity of KOS-953, a Cremophor-Based Formulation of the hsp90 Inhibitor 17-AAG.. <i>Blood</i> , 2004 , 104, 2404-2404	2.2	3
203	PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo.. <i>Blood</i> , 2005 , 106, 247-247	2.2	3
202	Establishment of a Waldenstrom's Macroglobulinemia Cell Line (BCWM.1) with Productive In Vivo Engraftment in SCID-hu Mice.. <i>Blood</i> , 2005 , 106, 979-979	2.2	3
201	Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenstrom's Macroglobulinemia (WM).. <i>Blood</i> , 2006 , 108, 2490-2490 ^{2.2}		3
200	Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease. <i>Blood</i> , 2008 , 112, 2739-2739	2.2	3

199	Lack of Response to Vaccination in MGUS and Stable Myeloma.. <i>Blood</i> , 2009 , 114, 1852-1852	2.2	3
198	BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2010 , 116, 3060-3060 ²⁻²	2.2	3
197	Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016 , 128, 243-243	2.2	3
196	Author response: Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer 2014 ,		3
195	JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.. <i>Blood</i> , 2004 , 104, 3413-3413	2.2	3
194	The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Potent and Selective Cytotoxicity against CD138 Positive Multiple Myeloma Cells in Vitro and in Vivo.. <i>Blood</i> , 2008 , 112, 1716-1716 ³	2.2	3
193	A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. <i>Blood Advances</i> , 2018 , 2, 2400-2411	7.8	3
192	Monoclonal Gammopathy May Be of Unpredictable Significance. <i>JAMA Oncology</i> , 2019 , 5, 1302-1303	13.4	2
191	The monoclonal antibody nBT062 conjugated to maytansinoids has potent and selective cytotoxicity against CD138 positive multiple myeloma cells in vitro and in vivo. <i>Nature Precedings</i> , 2008 ,		2
190	Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma.. <i>Nature Communications</i> , 2022 , 13, 807	17.4	2
189	Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3210-3210	2.2	2
188	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated By Cgas/Sting Pathway Activation, Type I Interferon Secretion, and Immunogenic Cell Death: Clinical Application. <i>Blood</i> , 2020 , 136, 7-8	2.2	2
187	A Novel Orally Available Proteasome Inhibitor NPI-0052 Induces Killing in Multiple Myeloma (MM) Cells Resistant to Conventional and Bortezomib Therapies.. <i>Blood</i> , 2004 , 104, 2405-2405	2.2	2
186	Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.. <i>Blood</i> , 2004 , 104, 751-751	2.2	2
185	Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 1571-1571	2.2	2
184	Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenström Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response.. <i>Blood</i> , 2005 , 106, 980-980	2.2	2
183	The MEK1/2 Inhibitor AZD6244 (ARRY-142886) Downregulates Constitutive and Adhesion-Induced c-MAF Oncogene Expression and Its Downstream Targets in Human Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3463-3463	2.2	2
182	Anti-Myeloma Activity of the Small-Molecule Aurora Kinase Inhibitor VE465.. <i>Blood</i> , 2006 , 108, 3468-3468.2	2.2	2

181	Lenalidomide and Bortezomib Inhibit Osteoclast Differentiation and Activation in Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2006 , 108, 3485-3485	2.2	2
180	Anti-Myeloma Activity of Selective PI-3K/PDK/mTOR Inhibitor BEZ235.. <i>Blood</i> , 2007 , 110, 1185-1185	2.2	2
179	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4496-4496	2.2	2
178	Blockade of XBP1 Splicing by Inhibition of IRE1 β s a Promising Therapeutic Option in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 133-133	2.2	2
177	Elevated APE1 Mediates Dysregulation of Homologous Recombination in Myeloma: Mechanisms and Translational Significance. <i>Blood</i> , 2014 , 124, 2074-2074	2.2	2
176	Multimorbidity patterns and their association with survival in a large national cohort of older veterans with multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8033-8033	2.2	2
175	Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single cell level by QM-FISH. <i>Blood Advances</i> , 2021 ,	7.8	2
174	Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121). <i>Blood</i> , 2021 , 138, 2835-2835	2.2	2
173	RAD51 Inhibitor Reverses Etoposide-Induced Genomic Toxicity and Instability in Esophageal Adenocarcinoma Cells 2020 , 2, 3-9		2
172	Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 166	7	2
171	Activity of CDK1/2 Inhibitor LCQ195 Against Multiple Myeloma Cells.. <i>Blood</i> , 2007 , 110, 1519-1519	2.2	2
170	Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma. <i>Blood</i> , 2008 , 112, 3689-3689	2.2	2
169	Characteristics of neurotoxicity associated with icleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 8036-8036	2.2	2
168	Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System. <i>Cancers</i> , 2021 , 13,	6.6	2
167	Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021 , 5, 2982-2986	7.8	2
166	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101217	2.2	2
165	Solitary Extramedullary Multiple Myeloma Presenting with Small Bowel Obstruction. <i>Journal of Emergency Medicine</i> , 2016 , 50, e25-7	1.5	1
164	Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 374-5		1

163	Management Strategies for Relapsed Multiple Myeloma. <i>American Journal of Cancer</i> , 2006 , 5, 393-409		1
162	Enhancing the Immune Surveillance in Multiple Myeloma Via CDK4/6 Inhibition. <i>Blood</i> , 2020 , 136, 33-34	2.2	1
161	ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application. <i>Blood</i> , 2020 , 136, 51-51	2.2	1
160	Discovery of a Novel Mechanism of Resistance to Thalidomide Derivatives. <i>Blood</i> , 2018 , 132, 949-949	2.2	1
159	Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8+ cytotoxic T Lymphocytes Against Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3195-3195	2.2	1
158	Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Multiple Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD). <i>Blood</i> , 2020 , 136, 11-11	2.2	1
157	Requirement of Caspase-8 Versus Caspase-9 during Apoptosis in Multiple Myeloma Cells Induced by Bortezomib- or a Novel Proteasome Inhibitor NPI-0052.. <i>Blood</i> , 2005 , 106, 3378-3378	2.2	1
156	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 3380-3380	2.2	1
155	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. <i>Blood</i> , 2006 , 108, 3460-3460	2.2	1
154	Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.. <i>Blood</i> , 2007 , 110, 284-284	2.2	1
153	Combination of a Novel Proteasome Inhibitor NPI-0052 and Lenalidomide Trigger in Vivo Synergistic Cytotoxicity in Multiple Myeloma. <i>Blood</i> , 2008 , 112, 3662-3662	2.2	1
152	A Novel SIRT1 Activator SIRT1720 Triggers In Vitro and In Vivo Cytotoxicity In Multiple Myeloma Via ATM-Dependent Mechanism. <i>Blood</i> , 2010 , 116, 3007-3007	2.2	1
151	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2011 , 118, 1874-1874	2.2	1
150	Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2913-2913	2.2	1
149	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. <i>Blood</i> , 2011 , 118, 3966-3966	2.2	1
148	Differences in the Angiogenic Response and Subsequent Growth of Plasma Cells From Myeloma and MGUS Patients Xenografted Into Zebrafish Embryos.. <i>Blood</i> , 2012 , 120, 2912-2912	2.2	1
147	Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients. <i>Blood</i> , 2014 , 124, 638-638	2.2	1
146	Dysregulation of SHFM1, a Novel Target for Prevention of Genomic Instability in Myeloma, Is Associated with Epigenetic Changes at Specific CpG Sites. <i>Blood</i> , 2014 , 124, 862-862	2.2	1

145	Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Reverse Immunosuppression in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2106-2106	2.2	1
144	A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications. <i>Blood</i> , 2016 , 128, 356-356	2.2	1
143	Efficacy of siltuximab in patients with previously treated multicentric Castleman's disease (MCD).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8514-8514	2.2	1
142	Effect of siltuximab on lean body mass (LBM) in multicentric Castleman's disease (MCD) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8576-8576	2.2	1
141	IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. <i>Blood</i> , 2021 , 138, 1980-1985	2.2	1
140	Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial. <i>Blood</i> , 2021 , 138, 1739-1739	2.2	1
139	Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells. <i>Blood</i> , 2021 , 138, 2655-2655	2.2	1
138	Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3839-3839	2.2	1
137	Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3044-3044	2.2	1
136	In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones. <i>Blood</i> , 2021 , 138, 77-77	2.2	1
135	Increased TCF-4 Expression Correlates with Reduced Caspase-3 Induction and Confers Resistance to Bortezomib.. <i>Blood</i> , 2004 , 104, 285-285	2.2	1
134	Novel Hydroxamic Acid-Derived HDAC Inhibitor LBH589 Potently Activates Intrinsic and Extrinsic Apoptotic Pathways, and Induces Tubulin Hyperacetylation in Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 1578-1578	2.2	1
133	A Green Tea Polyphenol, Epigallocatechin-3-Gallate, Induces Selective Apoptosis in Multiple Myeloma Cells: Mechanism of Action and Therapeutic Potential.. <i>Blood</i> , 2005 , 106, 1590-1590	2.2	1
132	The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.. <i>Blood</i> , 2006 , 108, 3452-3452	2.2	1
131	Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control. <i>Blood</i> , 2018 , 132, 4500-4500	2.2	1
130	Revealing the impact of recurrent and rare structural variants in multiple myeloma		1
129	Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 27-27	2.2	1
128	The Multiple Myeloma Genome Project: Development of a Molecular Segmentation Strategy for the Clinical Classification of Multiple Myeloma. <i>Blood</i> , 2016 , 128, 196-196	2.2	1

127	Biological and Therapeutic Potential of Mir-155, 585 and Let-7f in Myeloma in Vitro and In Vivo.. <i>Blood</i> , 2009 , 114, 833-833	2.2	1
126	Identification of Significant Barriers to Accrual (BtA) to NCI Sponsored Multiple Myeloma [Clinical Trials (MM-CT): A Step towards Improving Accrual to Clinical Trials.. <i>Blood</i> , 2012 , 120, 3165-3165	2.2	1
125	Second primary malignancies (SPM) in African American (AA) and white patients with multiple myeloma in the National Veterans Affairs (VA) healthcare system.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10507-10507	2.2	1
124	CD44 v5 domain inhibition represses the polarization of Th2 cells by interfering with the IL-4/IL-4R signaling pathway. <i>Immunology and Cell Biology</i> , 2021 ,	5	1
123	Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. <i>Blood Cancer Journal</i> , 2021 , 11, 13	7	1
122	The DNA methylation landscape of multiple myeloma shows extensive inter- and inpatient heterogeneity that fuels transcriptomic variability. <i>Genome Medicine</i> , 2021 , 13, 127	14.4	1
121	Dendritic Cells and Peptide-Based Vaccine In Multiple Myeloma 2013 , 131-154		1
120	Activation of the ERK Pathway Drives Acquired Resistance to Venetoclax in MM Cell Models. <i>Blood</i> , 2020 , 136, 21-22	2.2	0
119	Disruption of the m-SWI/SNF Complex Mediated By Recurrent Non-Coding Mutations in BCL7A Induces Tumor Cell Proliferation in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 40-40	2.2	0
118	Functional dissection of inherited non-coding variation influencing multiple myeloma risk.. <i>Nature Communications</i> , 2022 , 13, 151	17.4	0
117	CD27-Mediated Apoptosis Is Dependent on Siva-Induced Caspase Activation in Human Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 3398-3398	2.2	0
116	Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401). <i>Blood</i> , 2021 , 138, 899-899	2.2	0
115	Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 545-545	2.2	0
114	Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study. <i>Blood</i> , 2021 , 138, 400-400	2.2	0
113	Enhanced CD138 peptide-specific cytotoxic T lymphocyte activities against breast, colon and pancreatic cancers in combination with pembrolizumab (anti-PD1).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e14302-e14302	2.2	0
112	Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle. <i>Blood</i> , 2010 , 116, 1963-1963	2.2	0
111	Disease-Associated Changes In The Repair Efficiency Of Double Strand Breaks Affect Melphalan Sensitivity Of The Bone Marrow Plasma Cells and Correlate With The Clinical Outcome Of Anti-Myeloma Therapy. <i>Blood</i> , 2013 , 122, 3723-3723	2.2	0
110	Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinoma. <i>Communications Biology</i> , 2021 , 4, 617	6.7	0

109	In Vitro Silencing of lncRNAs Using LNA GapmeRs. <i>Methods in Molecular Biology</i> , 2021 , 2348, 157-166	1.4	○
108	CRISPR Interference (CRISPRi) and CRISPR Activation (CRISPRa) to Explore the Oncogenic lncRNA Network. <i>Methods in Molecular Biology</i> , 2021 , 2348, 189-204	1.4	○
107	Reply to M. Roschewski et al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 478	2.2	
106	Pomalidomide for the treatment of relapsed and refractory multiple myeloma. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 1089-1108	1.1	
105	RNA Regulator of Lipogenesis (RROL) Is a Novel lncrna Mediating Protein-Protein Interaction at Gene Regulatory Loci Driving Lipogenic Programs in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 20-21	2.2	
104	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. <i>Blood</i> , 2020 , 136, 8-8	2.2	
103	A Novel CD138-Targeting Monoclonal Antibody Induces Potent Myeloma Killing and Further Synergizes with IMiDs or Bortezomib in in Vitro and In Vivo Preclinical Models of Human Multiple Myeloma. <i>Blood</i> , 2020 , 136, 30-31	2.2	
102	TRAF2 Mediates Sensitivity to Immunomodulatory Drugs in the Bone Marrow Microenvironment. <i>Blood</i> , 2020 , 136, 31-31	2.2	
101	Atpase Family AAA Domain-Containing Protein 2 (ATAD2) As a Novel Target in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 50-50	2.2	
100	A High Throughput Functional Screen Identifies a Novel Apex Inhibitor: Augments Cytotoxicity While Significantly Decreasing Genomic Evolution in Myeloma. <i>Blood</i> , 2020 , 136, 10-11	2.2	
99	A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts. <i>Blood</i> , 2020 , 136, 1-2	2.2	
98	Exploring POU2AF1 (BOB-1) Dependency and Transcription Addiction in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 49-49	2.2	
97	Genomic and Transcriptomic Characterization of IgM Multiple Myeloma Identifies a Pre-Germinal Center Plasma Cell Disorder with Immature B-Cell Transcription-Factor Signature. <i>Blood</i> , 2020 , 136, 7-8	2.2	
96	Base Excision Repair and Homologous Recombination Pathway Intermediates Drive Genomic Instability and Evolution in Myeloma. <i>Blood</i> , 2020 , 136, 27-28	2.2	
95	Targeting MM at the Nexus between Cell Cycle and Transcriptional Regulation Via CDK7 Inhibition. <i>Blood</i> , 2020 , 136, 1-2	2.2	
94	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 4082-4082	2.2	
93	B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication. <i>Blood</i> , 2021 , 138, 2670-2670	2.2	
92	Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 461-461	2.2	

- 91 Transcriptional Deregulation Mediated By ID2-TCF3 Axis Supports MM Cell Growth and Proliferation in the Context of the Bone Marrow Milieu. *Blood*, **2021**, 138, 2686-2686 2.2
- 90 Decreasing Costs and Clinic Wait Time While Maintaining Safety for Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) for Multiple Myeloma. *Blood*, **2021**, 138, 666-666 2.2
- 89 16p Deletion Involving BCMA Locus Is Frequent and Predominantly Observed with del17p. *Blood*, **2021**, 138, 1590-1590 2.2
- 88 Rejuvenated BCMA-Specific CD8 + Cytotoxic T Lymphocytes Derived from Antigen-Specific Induced Pluripotent Stem Cells : Immunotherapeutic Application in Multiple Myeloma. *Blood*, **2021**, 138, 75-75 2.2
- 87 A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. *Blood*, **2021**, 138, 1650-1650 2.2
- 86 Clonal Hematopoiesis Is Frequent and Associated with Inferior Survival Irrespective of Transplantation Strategy in Patients with Newly Diagnosed Multiple Myeloma. *Blood*, **2021**, 138, 1127-1127 2.2
- 85 Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability. *Blood*, **2021**, 138, 2687-2687 2.2
- 84 PDC-E2, a Common Auto Antigen in Primary Biliary Cirrhosis (PBC) Is Also a Target of an Antibody Response in Patients Who Achieve Complete Remission after Donor Lymphocyte Infusion.. *Blood*, **2004**, 104, 2121-2121 2.2
- 83 A Clinically Relevant SCID-hu in Vivo Model of Human Multiple Myeloma.. *Blood*, **2004**, 104, 2455-2455 2.2
- 82 Molecular Mechanisms Underlying the Development of Drug Resistance in Multiple Myeloma.. *Blood*, **2004**, 104, 3409-3409 2.2
- 81 Enhanced Cytotoxicity of Monoclonal Antibody SGN-40 and Immunomodulatory Drug IMiD3 Against Human Multiple Myeloma.. *Blood*, **2004**, 104, 1498-1498 2.2
- 80 Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. *Blood*, **2004**, 104, 2401-2401 2.2
- 79 SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.. *Blood*, **2004**, 104, 3466-3466 2.2
- 78 Induction of Multiple Myeloma-Specific Cytotoxic T Lymphocytes Using HLA-A2.1-Specific CD19 and CD20 Peptides.. *Blood*, **2004**, 104, 2477-2477 2.2
- 77 Evaluation of the Ras/B-Raf/SHP-2 Axis in B Cell Malignancies.. *Blood*, **2004**, 104, 4344-4344 2.2
- 76 Tumor Antigen Immunization of Sibling Stem Cell Transplant Donors in Multiple Myeloma.. *Blood*, **2004**, 104, 3340-3340 2.2
- 75 Targeting Mitochondrial Factor Smac/DIABLO as Therapy for Multiple Myeloma (MM).. *Blood*, **2004**, 104, 764-764 2.2
- 74 Alkylphosphocholine Perifosine Inhibits Myeloma Cell Growth While Inducing Myeloid Hyperplasia in a Murine Myeloma Model.. *Blood*, **2005**, 106, 1579-1579 2.2

73	Chromosomal Deletions and Amplifications in Multiple Myeloma Detected by 500K Single Nucleotide Polymorphism Array Analysis.. <i>Blood</i> , 2005 , 106, 1551-1551	2.2
72	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40-Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications.. <i>Blood</i> , 2005 , 106, 5150-5150	2.2
71	Role of BAFF in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment.. <i>Blood</i> , 2005 , 106, 627-627	2.2
70	In Vitro Generation of Highly-Purified Functional Invariant NKT Cells: A Strategy for Immunotherapy in Multiple Myeloma.. <i>Blood</i> , 2005 , 106, 5183-5183	2.2
69	Dysfunctional T Regulatory Cells in Myeloma: Molecular Mechanisms of Dysregulation.. <i>Blood</i> , 2005 , 106, 3462-3462	2.2
68	Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM).. <i>Blood</i> , 2005 , 106, 5153-5153	2.2
67	Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3080-3080	2.2
66	Critical Role of Recombinase (HsRAD51) in Genetic Instability in Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 2078-2078	2.2
65	Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3396-3396	2.2
64	A Novel Real-Time In Vivo Homing Model of Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 242-242	2.2
63	Elevated Apurinic/Apyrimidinic Endonuclease Activity Significantly Contributes to DNA Instability in Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 2077-2077	2.2
62	Physical and Functional Association of the MRN Complex with Human Telomerase in Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 5076-5076	2.2
61	Clinical, Radiographic, and Biomarker Characterization of Multiple Myeloma Patients with Bisphosphonate Associated Osteonecrosis of the Jaw.. <i>Blood</i> , 2006 , 108, 3591-3591	2.2
60	In Vitro Generation of Highly Purified Functional Invariant NKT Cells in Multiple Myeloma: A Strategy for Immunotherapy.. <i>Blood</i> , 2006 , 108, 5104-5104	2.2
59	Bcl-2, Mcl-1 and p53 Expression Confer Sensitivity to Bcl-2 Inhibitor ABT-737 in Multiple Myeloma.. <i>Blood</i> , 2006 , 108, 3474-3474	2.2
58	OFD1-Mediated T Cell Responses in MGUS Patients: Implications for Immunotherapy.. <i>Blood</i> , 2007 , 110, 1488-1488	2.2
57	Combination of Proteasome Inhibitors Bortezomib and NPI-0052 Trigger In Vivo Synergistic Cytotoxicity in Multiple Myeloma.. <i>Blood</i> , 2007 , 110, 2524-2524	2.2
56	Plasmacytoid Dendritic Cells Induce Growth and Survival of Multiple Myeloma Cells: Therapeutic Application.. <i>Blood</i> , 2007 , 110, 3507-3507	2.2

55	Modulation of Gene Expression Profile and In Vivo Anti-Myeloma Activity Induced by Valproic Acid, a Histone Deacetylase Inhibitor.. <i>Blood</i> , 2007 , 110, 4790-4790	2.2
54	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007 , 110, 4494-4494	2.2
53	Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications. <i>Blood</i> , 2018 , 132, 1925-1925	2.2
52	Selective Targeting of Multiple Myeloma By Bcma-Specific Central Memory CD8+ cytotoxic T Lymphocytes: A Potential Immunotherapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders. <i>Blood</i> , 2018 , 132, 3196-3196	2.2
51	Time to Development of Treatment-Emergent Extramedullary and Osseous Plasmacytomas in the Era of Novel Agents: An Analysis of Upfront Regimens in Newly Diagnosed MM Incorporating Lenalidomide and Bortezomib. <i>Blood</i> , 2014 , 124, 3468-3468	2.2
50	Cytoskeleton Regulator PAK4 Plays a Role in Growth and Survival of Myeloma with a Potential Therapeutic Intervention Using PAK4 Allosteric Modulators (PAMs). <i>Blood</i> , 2014 , 124, 3381-3381	2.2
49	IL-17A-Mediated Notch Signaling in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 3434-3434	2.2
48	Mimicking Myeloma Niche Ex Vivo. <i>Blood</i> , 2014 , 124, 2076-2076	2.2
47	Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology. <i>Blood</i> , 2014 , 124, 3404-3404	2.2
46	Incidence and Clinical Features of Extramedullary Multiple Myeloma in Patients Who Underwent Stem Cell Transplantation. <i>Blood</i> , 2014 , 124, 5746-5746	2.2
45	Long Intergenic Non-Coding RNAs (lincRNA) Impacts Biology and Clinical Outcome in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 642-642	2.2
44	Differential and Limited Expression of Mutant Alleles in Multiple Myeloma. <i>Blood</i> , 2014 , 124, 2007-2007	2.2
43	Inter and Intra-Clonal Heterogeneity in Multiple Myeloma and Waldenstrom Macroglobulinemia. <i>Blood</i> , 2014 , 124, 2070-2070	2.2
42	Dysregulated Nucleotide Excision Repair (NER) Is a New Target in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 4187-4187	2.2
41	Selective Activation of the Non-Classical Estrogen Receptor Gper Elicits Potent Anti-Tumor Activity in Multiple Myeloma. <i>Blood</i> , 2015 , 126, 916-916	2.2
40	ABL Tyrosine Kinase Plays an Important Role in Mechanisms Involved in Genomic Instability in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 2087-2087	2.2
39	ILF2-YB1 Protein Interaction Modulates RNA Splicing to Induce Resistance to Chemotherapy in High Risk Multiple Myeloma. <i>Blood</i> , 2016 , 128, 359-359	2.2
38	Global Genomic Analysis of Newly Diagnosed t(4;14) Multiple Myeloma Reveals a Specific Mutational Spectrum and Identifies PKD2 As a Potential Therapeutic Target. <i>Blood</i> , 2016 , 128, 4462-4462	2.2

37	The Complex Landscape of Rearrangements in Smoldering and Symptomatic Multiple Myeloma Revealed By Whole-Genome Sequencing. <i>Blood</i> , 2016 , 128, 236-236	2.2
36	Deubiquitylating Enzyme USP1 As Therapeutic Target in Multiple Myeloma. <i>Blood</i> , 2016 , 128, 3290-3290	2.2
35	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. <i>Blood</i> , 2016 , 128, 237-237	2.2
34	Flap Structure-Specific Endonuclease 1 (FEN1) May be a Key Mediator of Genome Instability in Myeloma: A Cellular Vulnerability with Potential Therapeutic Significance. <i>Blood</i> , 2016 , 128, 4440-4440	2.2
33	Chromatin Histone Modifying and DNA Repair Inhibition Enhances the Anti-Myeloma Activity of Melphalan. <i>Blood</i> , 2016 , 128, 4437-4437	2.2
32	Sp1 Transcription Factor as a Novel Therapeutic Target in Multiple Myeloma (MM). <i>Blood</i> , 2008 , 112, 3664-3664	2.2
31	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. <i>Blood</i> , 2008 , 112, 2737-2737	2.2
30	Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. <i>Blood</i> , 2009 , 114, 1722-1722	2.2
29	Molecular Sequaele of Activin A-Dependent Osteoblast Inhibition in Myeloma.. <i>Blood</i> , 2009 , 114, 1789-1789	2.2
28	Immunomodulatory EFFECTS of Lenalidomide and Pomalidomide ON INTERACTION of TUMOR and BONE MARROW Accessory CELLS IN MULTIPLE MYELOMA.. <i>Blood</i> , 2009 , 114, 950-950	2.2
27	AT9283, a Small Molecule Multi-Targeted Kinase Inhibitor Induces Antimyeloma Activity Via Potent Aurora Kinase and STAT3 Inhibition.. <i>Blood</i> , 2009 , 114, 3833-3833	2.2
26	A NOVEL Aurora A Kinase INHIBITOR MLN8237 Induces Cytotoxicity and CELL Cycle Arrest IN MULTIPLE MYELOMA.. <i>Blood</i> , 2009 , 114, 3830-3830	2.2
25	Significant Biological Role of Sp1 Transactivation in Myeloma: Potential Therapeutic Application.. <i>Blood</i> , 2009 , 114, 1841-1841	2.2
24	Bcl6 as a Novel Therapeutic Target in Multiple Myeloma (MM).. <i>Blood</i> , 2009 , 114, 295-295	2.2
23	An Investigational Novel Orally Bioavailable Proteasome Inhibitor MLN9708/MLN2238 Triggers Cytotoxicity In Multiple Myeloma Cells Via p21- and Caspase-8-Dependent Signaling Pathway. <i>Blood</i> , 2010 , 116, 2992-2992	2.2
22	Anti-Myeloma Activity of Enzymatically Activated Melphalan Prodrug J1. <i>Blood</i> , 2010 , 116, 1838-1838	2.2
21	Bone Marrow Niche Down-Regulates Mir-30 In Multiple Myeloma Cells to Promote Cancer Progression and Cancer Initiation by Targeting BCL9/Wnt Pathway.. <i>Blood</i> , 2010 , 116, 1569-1569	2.2
20	Compartment-Specific Bioluminescence Imaging Platform for the Open-Ended Identification of Novel Immunomodulatory Agents and High-Throughput Evaluation of Anti-Tumor Immune Function. <i>Blood</i> , 2010 , 116, 451-451	2.2

19	Targeting Sp1 Transactivation In Waldenstrom's Macroglobulinemia: a Novel Therapeutic Option. <i>Blood</i> , 2010 , 116, 120-120	2.2
18	Gene Mutations Detected by Whole-Exome Sequencing and Recurrent Cytogenetic Abnormalities Are Independent Events in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 1816-1816	2.2
17	Novel Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders,. <i>Blood</i> , 2011 , 118, 3990-3990	2.2
16	MiR-34a Replacement As a Novel Therapeutic Approach for Multiple Myeloma: Preclinical In Vitro and In Vivo Evidence. <i>Blood</i> , 2011 , 118, 2910-2910	2.2
15	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. <i>Blood</i> , 2011 , 118, 815-815	2.2
14	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011 , 118, 4134-4134	2.2
13	Proteasome Inhibitors Sensitize Myeloma Cells to T Cell-Mediated Killing. <i>Blood</i> , 2011 , 118, 1838-1838	2.2
12	Myeloid Derived Suppressor Cells (MDSCs) Regulate Tumor Growth, Immune Response and Regulatory T Cell (Treg) Development in the Multiple Myeloma Bone Marrow Microenvironment. <i>Blood</i> , 2012 , 120, 565-565	2.2
11	Integrating Gene and Mir Expression Profiles and Regulatory Network Structures to Define Aberrant Feed Forward Loops with Functional and Clinical Implications in Myeloma.. <i>Blood</i> , 2012 , 120, 2386-2386	2.2
10	Characterization of TFDP1 As Novel Regulatory Gene in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 569-569	2.2
9	Formation of the Functional Niche in Vitro by Mimicking the Pathophysiological Features of the Bone Marrow Microenvironment in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 1812-1812	2.2
8	Role Of Base Excision Repair Associated AP Nuclease Activity In The Induction Of Homologous Recombination Repair Pathway and Survival Of MM Cells Following DNA Damage. <i>Blood</i> , 2013 , 122, 1248-1248	2.2
7	Constitutive B-Cell Maturation Antigen (BCMA) Activation In Human Multiple Myeloma Cells Promotes Myeloma Cell Growth and Survival In The Bone Marrow Microenvironment Via Upregulated MCL-1 and NF κ B Signaling. <i>Blood</i> , 2013 , 122, 681-681	2.2
6	Identification Of Novel Alternative Splice Variants Of Sirtuins In Multiple Myeloma: Therapeutic Implications. <i>Blood</i> , 2013 , 122, 3121-3121	2.2
5	Antitumor Activities Of An Oral Selective HSP90 α Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 4429-4429	2.2
4	Telomerase Contributes To Repair Of DNA Breaks In Myeloma Cells By Incorporating \square TAGGG \square Sequences Within Genome: Biological and Translational Significance. <i>Blood</i> , 2013 , 122, 1249-1249	2.2
3	Inhibition Of H3K27-Methylome As a Novel Therapeutic Strategy In Multiple Myeloma. <i>Blood</i> , 2013 , 122, 3162-3162	2.2
2	Elevated Nuclease Activity Correlates With Clinical Spectrum Of Plasma Cell Dyscrasias. <i>Blood</i> , 2013 , 122, 4885-4885	2.2

- 1 Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. *Journal of Clinical Oncology*, **2021**, 39, 12082-12082 2.2